Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Ovarian Neoplasms 2Lung Neoplasms 2Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 48Nivolumab 22Cyclophosphamide 10Carboplatin 10spartalizumab 8atezolizumab 7Gemcitabine 7130-nm albumin-bound paclitaxel 7fludarabine 6Cisplatin 6Ipilimumab 5durvalumab 4budigalimab 4avelumab 4Pemetrexed 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Leucovorin 4Irinotecan 4Interleukin-2 4Immune Checkpoint Inhibitors 4Docetaxel 4Bevacizumab 4cemiplimab 3cabozantinib 3aldesleukin 3Standard of Care 3Specimen Handling 3Oxaliplatin 3Fluorouracil 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × dehydroftorafur × Thoracic × Clear all
NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡